01 Growing Adoption of Advanced Absorbable Hemostatic Agents in Surgery The Hemostats Market trends are being driven by the increasing number of surgical procedures and the growing demand for products that can quickly control bleeding and reduce complications. These products are widely used in cardiovascular, orthopedic, neurological, and general surgeries, where rapid bleeding control is essential. The trend toward minimally invasive procedures is also encouraging the development of easy-to-apply hemostatic products compatible with laparoscopic and robotic surgeries. In March 2025, Teleflex Incorporated received U.S. FDA clearance for QuikClot Control+ Hemostatic Device, designed to control severe bleeding in surgical settings. The product combines kaolin-based technology with an improved delivery system, reflecting the industry's continued focus on innovative bleeding management solutions. Such advancements are strengthening the adoption of next-generation hemostatic products across hospitals worldwide.
02 Rising Innovation in Bioactive and Regenerative Hemostatic Technologies Another important Hemostats Market trend is the increasing development of bioactive and regenerative hemostatic materials that not only stop bleeding but also support wound healing. Manufacturers are investing in synthetic and biologically derived hemostats with improved biocompatibility, reduced infection risk, and faster tissue recovery. Healthcare providers are also adopting combination products that integrate sealing and hemostatic functions to improve surgical outcomes. For instance, in 2025, several leading medical device companies expanded their portfolios of absorbable surgical hemostats and sealants to support complex procedures in trauma care, cardiovascular surgery, and minimally invasive operations. These innovations are improving patient safety, reducing operating time, and reinforcing long-term growth in the Hemostats Market.
June 17, 2026 – Johnson & Johnson MedTech (Ethicon) launched the new SURGIFLO™ Hemostatic Matrix Kit with Thrombin, featuring a redesigned preparation system that is approximately 36% faster than the previous version while maintaining the same clinical performance. The product is intended to improve operating room efficiency during surgical bleeding management.
June 2, 2026 – Wilson-Cook Medical (Cook Medical) received U.S. FDA 510(k) clearance for its Hemospray Endoscopic Hemostat (HEMO-[X]), indicated for endoscopic gastrointestinal hemostasis. The clearance expands available options for managing non-variceal gastrointestinal bleeding through minimally invasive endoscopic procedures.
June 25, 2026 – The U.S. FDA approved a PMA supplement for Ethicon's SURGICEL® Absorbable Hemostats, authorizing manufacturing process improvements. The update supports continued production efficiency while maintaining product quality and regulatory compliance.
October 21, 2025 – Olympus Corporation introduced THUNDERBEAT™ II, a next-generation hybrid energy device designed for hemostatic cutting and vessel sealing in laparoscopic and open surgical procedures. The device provides multiple energy modes to improve bleeding control and tissue dissection during surgery.